Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Japan SLC,Inc.

Japan SLC,Inc.

Table of Contents
Table of Contents

Japan SLC conducts non-clinical studies in-house, including GLP-compliant safety studies and pharmacological efficacy evaluations using a wide range of disease models, in addition to supplying laboratory animals.

As a fully integrated contract research organization, the company provides comprehensive support from animal breeding to antibody production.

Features of Japan SLC,Inc.’s Contract Services for Non-Clinical Studies

GLP-Compliant Safety Studies

Japan SLC,Inc. conducts in-vitro and in-vivo safety studies in compliance with the GLP standard for pharmaceutical drugs and medical devices.
Testing includes cytotoxicity, acute toxicity, and pyrogenicity evaluations, as well as studies aligned with GMP and QMS standards for target products.

With a flexible testing framework, the company can accommodate both GLP and non-GLP studies, supporting research from the early development phase through commercialization.

Flexible Study Design with Extensive Disease Models in Animal

Japan SLC,Inc. possesses a diverse portfolio of disease models in animals —including diabetes (STZ-induced), hyperlipidemia, arthritis, and pulmonary fibrosis—enabling tailored study designs depending on clients’needs.
In addition to models that are induced by diet, surgical, and chemical, the company also conducts specialized studies using ferrets and rabbits.

Japan SLC,Inc. not only performs contract studies but also supplies these disease model animals for external research uses.

Comprehensive Capability in Animal Supply and Antibody Production

The company offers end-to-end services covering the entire research process—from supplying and breeding laboratory animals to conducting pharmacological, safety, and pharmacokinetic studies, and antibody production.
Both polyclonal and monoclonal antibodies can be produced, with additional services such as splenocyte or PBMC collection available.

This integrated system enables Japan SLC,Inc. to deliver animals, technologies, and testing systems in one streamlined package, customized to the clients’ research goals and timelines.

An Example of Disease Model Provided by Japan SLC,Inc.

OSK-KI: A Genetically Engineered Mouse Model for Alzheimer’s Disease Research

The OSK-KI (C57BL/6-Tg(OSK-KI)) is a genetically modified mouse designed to overproduce amyloid-β, serving as a highly reproducible model for Alzheimer’s disease research.

A patent application has been filed for the model, which is recognized for its clinical translatability. The use of the model requires a research license agreement depending on the intended application.

Japan SLC,Inc. provides a wide range of advanced genetically engineered animal models to support drug discovery and disease mechanism studies.

Reference: Japan SLC,Inc. official website (http://www.jslc.co.jp/animals/mouse.php)

Example of Non-Clinical Study Conducted by Japan SLC

Pharmacological, Pharmacokinetic, and Immunological Studies Using Various Disease Models

Japan SLC,Inc. conducts a wide array of non-clinical studies utilizing animal models such as STZ-induced diabetes, drug-induced arthritis, and pulmonary fibrosis diseases.

Both GLP and non-GLP studies are available, including immunogenicity (antibody production) assessments.

Study designs can be flexibly tailored to the research purpose and development stage.

Reference: Japan SLC,Inc. official website http://www.jslc.co.jp/service/tests.php

Company Information

Address3371-8 Koto-cho, Chuo-ku, Hamamatsu City, Shizuoka, Japan
Tel053-486-3155
Websitehttp://www.jslc.co.jp/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services